Barclays PLC Increases BioXcel Therapeutics Investment Despite Negative EPS Analysis

Barclays PLC has recently increased its investments in BioXcel Therapeutics, Inc. (BTAI) in a significant way. In the first quarter of 2023, Barclays escalated its holdings of BioXcel Therapeutics to 56,023 shares. Currently, these shares are valued at approximately $1,045,000.

Despite this investment, BioXcel Therapeutics reported a negative earnings per share of ($1.83) for the quarter ending August 14th, 2023. However, the biopharmaceutical company did see a quarterly revenue increase reporting quarterly revenue of $0.46 million.

Although the EPS was negative, the consensus rating for BTAI shares among various analysts is “Hold”. Moreover, the consensus target price for BTAI shares stands at $23.88. This suggests that analysts believe BioXcel Therapeutics has potential for growth, despite the current negative EPS.

Institutional investors have shown a keen interest in BioXcel Therapeutics. Northwestern Mutual Wealth Management Co. and Point72 Hong Kong Ltd., among others, have notably increased their stakes in the company. As it stands, these investors currently hold about 42.35% of the company’s stock.

A transcript of the company’s recent earnings call can be found here.

.

Share This Article

 

About the Author

Barclays PLC Increases BioXcel Therapeutics Investment Despite Negative EPS Analysis

Editor Prism MarketView